Arlene C Seña1, Jeannette Y Lee2, Jane Schwebke3, Susan S Philip4, Harold C Wiesenfeld5, Anne M Rompalo6, Robert L Cook7, Marcia M Hobbs1. 1. Department of Medicine, Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill. 2. Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock. 3. Department of Medicine, University of Alabama at Birmingham. 4. San Francisco Department of Public Health, California. 5. Department of Obstetrics and Gynecology, Magee-Women's Hospital of University of Pittsburgh Medical Center, Pennsylvania. 6. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 7. Departments of Epidemiology and Medicine, University of Florida, Gainesville.
Abstract
Background: Mycoplasma genitalium can result in pelvic inflammatory disease and adverse pregnancy outcomes. We analyzed data collected from a prospective study of asymptomatic bacterial vaginosis (BV) to determine the natural history of M. genitalium. Methods: Women aged 15-25 years, with asymptomatic BV and ≥2 risk factors for sexually transmitted infection were recruited from 10 sites throughout the United States. Vaginal swab samples were collected at enrollment and through home-based testing every 2 months over 12 months. M. genitalium nucleic acid amplification testing was performed for M. genitalium using transcription-mediated assays (Hologic). The prevalence, incidence, and persistence of M. genitalium, defined as all positive specimens during follow-up, were estimated with 95% confidence intervals (CIs). Adjusted odds ratios (AOR) were calculated using logistic and Poisson regression to evaluate participant characteristics associated with M. genitalium infection. Results: Among 1139 women, 233 were M. genitalium positive, for a prevalence of 20.5% (95% CI, 18.2%-22.9%); 42 of 204 had persistent M. genitalium (20.6%). Among 801 M. genitalium-negative women at baseline, the M. genitalium incidence was 36.6 per 100 person-years (95% CI, 32.4-41.3). Black race (AOR, 1.92; 95% CI, 1.09-3.38), age ≤21 years (1.40; 1.03-1.91), and prior pregnancy (1.36; 1.00-1.85) were associated with prevalent M. genitalium; only black race was associated with incident M. genitalium (P = .03). Conclusions: We identified high rates of prevalent, incident, and persistent M. genitalium infections among young, high-risk women with asymptomatic BV, supporting the need for clinical trials to evaluate the impact of M. genitalium screening on female reproductive health outcomes.
Background: Mycoplasma genitalium can result in pelvic inflammatory disease and adverse pregnancy outcomes. We analyzed data collected from a prospective study of asymptomatic bacterial vaginosis (BV) to determine the natural history of M. genitalium. Methods:Women aged 15-25 years, with asymptomatic BV and ≥2 risk factors for sexually transmitted infection were recruited from 10 sites throughout the United States. Vaginal swab samples were collected at enrollment and through home-based testing every 2 months over 12 months. M. genitalium nucleic acid amplification testing was performed for M. genitalium using transcription-mediated assays (Hologic). The prevalence, incidence, and persistence of M. genitalium, defined as all positive specimens during follow-up, were estimated with 95% confidence intervals (CIs). Adjusted odds ratios (AOR) were calculated using logistic and Poisson regression to evaluate participant characteristics associated with M. genitaliuminfection. Results: Among 1139 women, 233 were M. genitalium positive, for a prevalence of 20.5% (95% CI, 18.2%-22.9%); 42 of 204 had persistent M. genitalium (20.6%). Among 801 M. genitalium-negative women at baseline, the M. genitalium incidence was 36.6 per 100 person-years (95% CI, 32.4-41.3). Black race (AOR, 1.92; 95% CI, 1.09-3.38), age ≤21 years (1.40; 1.03-1.91), and prior pregnancy (1.36; 1.00-1.85) were associated with prevalent M. genitalium; only black race was associated with incident M. genitalium (P = .03). Conclusions: We identified high rates of prevalent, incident, and persistent M. genitaliuminfections among young, high-risk women with asymptomatic BV, supporting the need for clinical trials to evaluate the impact of M. genitalium screening on female reproductive health outcomes.
Authors: Harold C Wiesenfeld; Sharon L Hillier; Marijane A Krohn; Daniel V Landers; Richard L Sweet Journal: Clin Infect Dis Date: 2003-02-07 Impact factor: 9.079
Authors: Victoria L Mobley; Marcia M Hobbs; Karen Lau; Barbara S Weinbaum; Damon K Getman; Arlene C Seña Journal: Sex Transm Dis Date: 2012-09 Impact factor: 2.830
Authors: Jane R Schwebke; Jeannette Y Lee; Shelly Lensing; Susan S Philip; Harold C Wiesenfeld; Arlene C Seña; Nikole Trainor; Nincoshka Acevado; Lisa Saylor; Ann M Rompalo; Robert L Cook Journal: Clin Infect Dis Date: 2015-11-26 Impact factor: 9.079
Authors: Judith Vandepitte; Helen A Weiss; Justine Bukenya; Nassim Kyakuwa; Etienne Muller; Anne Buvé; Patrick Van der Stuyft; Richard J Hayes; Heiner Grosskurth Journal: Sex Transm Infect Date: 2014-03-31 Impact factor: 3.519
Authors: Judith Vandepitte; Helen A Weiss; Nassim Kyakuwa; Susan Nakubulwa; Etienne Muller; Anne Buvé; Patrick Van der Stuyft; Richard Hayes; Heiner Grosskurth Journal: Sex Transm Dis Date: 2013-05 Impact factor: 2.830
Authors: Li Xiao; Ken B Waites; Barbara Van Der Pol; Kristal J Aaron; Edward W Hook; William M Geisler Journal: Sex Transm Dis Date: 2019-01 Impact factor: 2.830
Authors: Laarni Kendra T Aguila; Dorothy L Patton; German G Gornalusse; Lucia N Vojtech; Robert D Murnane; Gwendolyn E Wood Journal: Infect Immun Date: 2022-05-18 Impact factor: 3.609
Authors: Alexander Ring; Suraj Balakrishna; Frank Imkamp; Sara Burkard; Flurina Triet; Flurina Brunschweiler; Christina Grube; Rebecca Bodmer; Roger D Kouyos; Huldrych F Günthard; Dominique L Braun Journal: Open Forum Infect Dis Date: 2022-04-27 Impact factor: 4.423
Authors: Sarah S Romano; Jørgen S Jensen; M Sylvan Lowens; Jennifer L Morgan; Laura C Chambers; Tashina S Robinson; Patricia A Totten; Olusegun O Soge; Matthew R Golden; Lisa E Manhart Journal: Clin Infect Dis Date: 2019-06-18 Impact factor: 9.079
Authors: Stephen D Gragg; Kanupriya A Gupta; Kristin M Olson; Barbara Van Der Pol; Li Xiao; Ken B Waites; William M Geisler Journal: Sex Transm Dis Date: 2021-02-01 Impact factor: 3.868
Authors: Irene A Stafford; Kelsey Hummel; James J Dunn; Kenneth Muldrew; Alexandra Berra; Elizabeth Skye Kravitz; Soumya Gogia; Irene Martin; Erik Munson Journal: BMJ Open Date: 2021-06-14 Impact factor: 2.692
Authors: P Madhivanan; K Krupp; M Coudray; B Colbert; D Ruiz-Perez; H Cui; N Bokulich; G Narasimhan; K Mathee; R L Cook; J Schwebke; D Roe Journal: Vaccine Date: 2021-07-20 Impact factor: 4.169
Authors: Gwendolyn E Wood; Stefanie L Iverson-Cabral; Catherine W Gillespie; M Sylvan Lowens; Lisa E Manhart; Patricia A Totten Journal: PLoS One Date: 2020-10-12 Impact factor: 3.240